A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 33,183 shares of HALO stock, worth $1.61 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
33,183
Holding current value
$1.61 Million
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$51.3 - $64.42 $1.7 Million - $2.14 Million
33,183 New
33,183 $1.9 Billion

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.75B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track B. Metzler Seel. Sohn & Co. Holding Ag Portfolio

Follow B. Metzler Seel. Sohn & Co. Holding Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Holding Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Holding Ag with notifications on news.